Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • jelly1126 jelly1126 May 10, 2011 3:51 PM Flag

    Dacogen Post 2013

    We all know that Dacogen is slated to go off patent in November of 2013. The way I understand it, if it is approved for AML, Dacogen could get an additional 6 months of exclusivity. Still, as we all know, it won't be very long before Dacogen gets competition from generic manufacturers.

    My question, however is, are any companies working on a generic version?

    If I remember, Dacogen was approved on an orphan drug status, and as a result, there is not a huge market for the drug. Adding AML to the list of approved indications might expand the market, but is it enough of an expansion to justify generics makers to try to develop an equivalent?

    Just curious...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • deb
      Eisai does not need to 'develop' a generic version of Dacogen. All they have to do is change the NDC number on the package and sell it at a generic price and its a generic. They could get a generic marketing partner if they dont want to do it themselves

      However since this drug has subtantial brand sales I am quite sure there will be multiple generic approvals from other companies and the price is likely to drop at least 80% from what the brand is now and since the market share will be split among multiple companies any roylaties will be negiligble.

      Watch what happens to Vidaza when the patent expires that will be a good modeling tool.

    • Jelly,

      Eisai has a generic division and has also partnered several drugs nearing generic versions. So what's to say that they take the next step and develope a generic version of dacogen? Supg receives royalities for 20 years all indications.

 
ASTX
8.4950.0000(0.00%)Oct 10 4:00 PMEDT